- ImmunoPrecise (OTCQB:IPATF) has entered into a research agreement with Genmab (NASDAQ:GMAB), wherein IPA will generate bispecific antibody combinations using Genmab's proprietary DuoBody platform and IPA's proprietary antibodies in the field of infectious disease.
- As a part of the partnership, Genmab and IPA will